Børn med hypodiploidi (10 -4 ved TP5 (Time Point 5) eller er HR (High Risk; alder10 -3 i marven. Børn i >2. CR Alle søges indstillet til HSCT hvis almentilstanden tillader det. Induction failure/resistent sygdom Generelt transplanteres kun patienter der på transplantationstidspunktet har MRD
i det nordamerikanske register, af størrelsesorden 80-90% inden<strong>for</strong> en søgetid på ca. tre måneder. Hvis der ikke kan lokaliseres matchende familie eller ubeslægtet (herunder NS-donor) donor inden <strong>for</strong> ca. tre måneder må muligheden <strong>for</strong> protokolleret haplotransplantation overvejes. Referencer K Schmiegelow, E Forestier, M Hellebostad, M Heyman, J Kristinsson, S Söderhäll and M Taskinen On behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO). Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24: 345-354 2010. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation <strong>for</strong> pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):62-71. Review. NOPHO – ALL 2008 Final protocol version 1e Treatment Protocol <strong>for</strong> Children (1.0 - 17.9 years of age) and young adults. (18-45 years of age) with Acute Lymphoblastic Leukemia. NOPHO hjemmeside. EsPhALL: Amendment proposal An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). January 2010. NOPHO hjemmeside. IntReALL 2010. International Study <strong>for</strong> Treatment of Childhood Relapsed ALL. A Randomised Phase III Study of the International BFM Study Group Conducted by the Resitstant Disease Committee. Extended Synopsis Version 22.01.2010. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol. 2008 Sep;9(9):873-83. Review. INTERFANT-06 International Collaborative Treatment Protocol <strong>for</strong> Infants Under One Year with Acute Lymphoblastic or Biphenotypic leukaemia. NOPHO Hjemmeside. Zweidler-McKay PA, Hilden JM. The ABCs of infant leukemia. Curr Probl Pediatr Adolesc Health Care. 2008 Mar;38(3):78-94. Review. Lausen,B.F.; Heilmann,C.; Vindeløv,L.; Jacobsen,N. Outcome of acute lymphoblastic leukemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor garfts. Bone Marrow Transplant. 22, 325-330 (1998). Saarinen-Pihkala UM, Gustafsson G, Carlsen N, Flaegstad T, Forestier E, Glomstein A, Kristinsson J, Lanning M, Schroeder H, Mellander L; Nordic Society of Pediatric Hematology and Oncology. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer. 2004 Jan;42(1):8-23. Saarinen-Pihkala UM, Gustafsson G, Ringdén O, Heilmann C, Glomstein A, Lönnerholm G, Abrahamsson J, Bekassy AN, Schroeder H, Mellander L; Nordic Society of Pediatric Hematology and Oncology. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors <strong>for</strong> bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol. 2001 Jul 15;19(14):3406-14. 25
- Page 1 and 2: Rekommandationer for knoglemarvstra
- Page 3 and 4: Vævstyper og terminologi Ved valg
- Page 5 and 6: 3.valg: 9/10 allel forligelig ubesl
- Page 7 and 8: Petersdorf EW et al: Major-histocom
- Page 9 and 10: Sygdomsspecifikke overvejelser & kr
- Page 11 and 12: Non myeloablativ stamcelletransplan
- Page 13 and 14: Akutte Leukæmier ALL hos voksne AL
- Page 15 and 16: En metaanalyse af 7 studier, hvor a
- Page 17 and 18: Højrisikofaktorer • Fænotype: N
- Page 19 and 20: Kemoterapi Hoelzer, D.F (1993). The
- Page 21 and 22: unrelated transplant in first compl
- Page 23: ALL hos børn 5% blaster i knoglema
- Page 27 and 28: Risikogrupper for AML i 1. CR Lavri
- Page 29 and 30: Autolog KMT Litteraturen på områd
- Page 31 and 32: Gale, R.P., Horowitz, M.M., Weiner,
- Page 33 and 34: myelogenous leukemia in first compl
- Page 35 and 36: AML hos børn
- Page 37 and 38: Eapen M, Rubinstein P, Zhang MJ, Ca
- Page 39 and 40: Point Parameter 0 0.5 1 1.5 2 Blast
- Page 41 and 42: *) Specielt i denne gruppe gælder
- Page 43 and 44: Kantarjian H, O'Brien S, Cortes J,
- Page 45 and 46: Scott BL, Sandmaier BM, Storer B, M
- Page 47 and 48: tiltagende. Patienter med RC og hø
- Page 49 and 50: Donor leukocyte infusion after hema
- Page 51 and 52: � Konstitutionelle symptomer, for
- Page 53 and 54: Responskriterier ved CML Responstyp
- Page 55 and 56: patienter, som statistisk set vil h
- Page 57 and 58: Mauro,M.J. (2006) Defining and mana
- Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
- Page 61 and 62: Der er ingen data, der indicerer at
- Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
- Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
- Page 67 and 68: Der er ikke indikation for autolog
- Page 69 and 70: sequential chemotherapy in poor-ris
- Page 71 and 72: af immunosuppressiv beh. og DLI og
- Page 73 and 74: following high-dose sequential chem
- Page 75 and 76:
Marginal Zone Lymfom Senest revider
- Page 77 and 78:
Rezvani AR, Storer B, Maris M et al
- Page 79 and 80:
eskriver også sammenhæng mellem i
- Page 81 and 82:
HCT ved refraktær sygdom (Verdonck
- Page 83 and 84:
transplantation for lymphoprolifera
- Page 85 and 86:
Perifere T-Celle Lymfomer Senest re
- Page 87 and 88:
Referencer: Evens AM, Gartenhaus RB
- Page 89 and 90:
Hodgkin Lymfom (HL) Senest revidere
- Page 91 and 92:
Patienter med progressiv sygdom ell
- Page 93 and 94:
Transplant, 12,172-183. Anderlini,P
- Page 95 and 96:
Allogen KMT 1. HLA-identisk søsken
- Page 97 and 98:
Referencer Definition Bacigalupo A,
- Page 99 and 100:
Paroxysmal Nocturn Haemoglobinuri,
- Page 101 and 102:
Autolog transplantation Myelomatose
- Page 103 and 104:
Cavo M, Tosi P, Zagmani E, Cellini
- Page 105 and 106:
Myelofibrose Idiopatisk myelofibros
- Page 107 and 108:
Introduktion Retransplantation af b
- Page 109 and 110:
Den samlede konklusion kunne være,
- Page 111 and 112:
Thalassæmier Senest revideret nove
- Page 113 and 114:
thalassæmifri overlevelse på 66%
- Page 115 and 116:
Kronisk granulomatøs sygdom Senest
Change language